Evaluation of cutaneous modifications in seventy-seven growth hormone-deficient children.

Centre de Recherche sur la Croissance, Pavillon Leriche, Centre Hospitalier Universitaire de Purpan, Toulouse, France.
Hormone Research (Impact Factor: 2.48). 02/2000; 54(2):92-7. DOI: 10.1159/000053238
Source: PubMed

ABSTRACT Cutaneous parameters such as dermal thickness, stiffness, elasticity, skin surface lipid and hydration were evaluated using noninvasive methods in 77 growth hormone-deficient (GHD) children before replacement therapy and in 70 non-GHD children. We showed that in GHD children, dermis was thinner (0.70 +/- 0.10 vs. 0.80 +/- 0.10 mm, p < 0.0001 for prepubertal children and 0.81 +/- 0.10 vs. 0.94 +/- 0.11 mm, p < 0.0001 for pubertal children), stiffer (178.5 +/- 57.3 vs. 113.09 +/- 37 kPa, p < 0.0001 for prepubertal children and 172.5 +/- 61.7 vs. 117.3 +/- 42.5 kPa for pubertal children, p < 0.001) and less elastic (0.44 +/- 0.09 vs. 0.39 +/- 0.06 (nonelasticity index), p < 0.01 for prepubertal children and 0.39 +/- 0.05 vs. 0.33 +/- 0.04, p < 0.001 for pubertal children) compared to controls. Fourteen GHD children were re-evaluated after 1 year of GH treatment: dermal thickness and skin stiffness were significantly improved (p < 0.001 and p < 0.05 respectively) while elasticity was not modified. During the same period, 11 controls did not show any significant cutaneous modification. IGF-1 values, but not IGFBP-3 values, correlated positively with dermal thickness in GHD children, before and after 1 year of GH treatment. To conclude, GHD children exhibited specific cutaneous modifications. In a subset of GHD children, we showed that these modifications were influenced by GH treatment. More extensive studies are needed to see if these changes correlated with other GH effects.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The eye represents a target site for GH action, although few data are available in patients with GH deficiency (GHD). Our aim was to evaluate central corneal thickness (CCT) and intraocular pressure (IOP) values in GHD children to assess the role played by GHD or GH treatment on these parameters. Design In 74 prepubertal GHD children (51 M, 23 F, aged 10.4 ± 2.4 years) we measured CCT and IOP before and after 12 months of treatment. A baseline evaluation was also made in 50 healthy children matched for age, gender and body mass index. The study outcome considered CCT and IOP during treatment and their correlations with biochemical and auxological data. Results No difference in CCT and IOP between GHD children at baseline and controls was found (all p > 0.005). GHD children after 12 months of therapy showed greater CCT (564.7 ± 13.1 μm) than both baseline values (535.7 ± 17 μm; p < 0.001) and control subjects (536.2 ± 12.5 μm; p < 0.001), with a concomitant higher corrected mean IOP (15.6 ± 0.7 mmHg; p < 0.001) than both baseline (12.5 ± 0.8 mmHg; p < 0.001) and controls (12.3 ± 0.5 mmHg; p < 0.001), without correlation with auxological and biochemical parameters. Conclusions 12 months of GH treatment in children with GHD, regardless of auxological and biochemical data, affect CCT and IOP. Our findings suggest careful ocular evaluation in these patients to prevent undesirable side effects during the follow-up.
    Growth Hormone & IGF Research 08/2014; · 1.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: SynopsisIrrespective of age, most of the skin components are under the physiological control of endocrine and neuroendocrine factors. There is evidence that skin ageing appears complex showing much interindividual variability. Conceptually, ageing is a single biological process that is influenced and modulated by a series of various internal and exogenous factors. Among them, hormones and neuroendocrine signals play key roles in several ways. Ageing of most endocrine glands will in turn alter the skin biology. In addition, the age-related reduction in the intrinsic neuroendocrine activity of the skin will also alter the ageing rate of this organ. At last, various endocrinopathies will boost or conversely decrease the severity of the signs of cutaneous ageing.RésuméIndépendamment de l’âge, la plupart des composants de la peau sont sous le contrôle physiologique de facteurs endocriniens et neuroendocriniens. Il semble évident, que le vieillissement cutané apparaît complexe, révélant une grande variabilité interindividuelle. Conceptuellement, le vieillissement est un processus biologique unique qui est influencé et modulé par une ensemble de divers facteurs internes et externes. Parmi eux, les hormones et les signaux neuroendocriniens jouent des rôles clés de diverses manières. D'une part, le vieillissement de la plupart des glandes endocrines va, par voie de conséquence, altérer la biologie cutanée. D'autre part, la réduction liée à l’âge de l'activité neuroendocrinienne intrinsèque de la peau altère aussi la progression du vieillissement de cet organe. Enfin, diverses endocrinopathies peuvent accélérer ou, en revanche, réduire la sévérité des signes du vieillissement cutané.
    International journal of cosmetic science 02/2007; 29(1):1 - 6.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper describes the growth hormone system, emphasizing its possible effects on epidermal cells, dermal structures and wound healing. A review of the literature was conducted on studies concerning the growth hormone molecule, its receptor and carrier proteins and the other proteins involved in the mechanisms of its manifestation in dermal tissue.
    Anais brasileiros de dermatologia 01/2011; 86(6):1159-65.